Rivier Delphine, Roy Sylvain, Mermoud André
Glaucoma Unit, Jules Gonin Eye Hospital, University of Lausanne, Lausanne, Switzerland.
J Cataract Refract Surg. 2007 Nov;33(11):1946-52. doi: 10.1016/j.jcrs.2007.06.069.
To evaluate the efficacy and safety of the Ex-PRESS R-50 implant (Optonol Ltd.) in eyes operated on for open-angle glaucoma combined with phacoemulsification.
Glaucoma Unit, Ophthalmology Department, University of Lausanne, Lausanne, Switzerland.
Between November 2000 and June 2002, the Ex-PRESS R-50 shunt was implanted in 35 eyes of 35 patients. The best corrected visual acuity (BCVA), intraocular pressure (IOP), number of medications, and complications were recorded preoperatively as well as postoperatively at 1 and 7 days and 1, 2, 3, 6, 9, 12, 24, 36, and 48 months. Temporal clear corneal phacoemulsification with intraocular lens implantation was performed first. The ophthalmic viscosurgical device was not removed, and the Ex-PRESS R-50 was implanted under the conjunctiva into the anterior chamber.
The mean follow-up was 36.9 months +/- 18.2 (SD) and the mean age of the patients, 74.6 +/- 10.9 years. The mean preoperative IOP of 19.3 +/- 6.3 mm Hg decreased postoperatively to 15.3 +/- 6.2 mm Hg, 15.1 +/- 4.6 mm Hg, 13.8 +/- 2.8 mm Hg, 14.6 +/- 2.9 mm Hg, and 13.3 +/- 2.0 mm Hg at 6 months, 12 months, 24 months, 36 months, and 48 months, respectively (P<.005). At 48 months, the mean BCVA was 0.74 +/- 0.34 and the number of medications was reduced by 57% (P<.005). The microtube was removed in 10 patients, and bleb management was performed in 10 eyes. Ten patients (32%) had satisfactory IOP control (mean 13.2 +/- 2.2 mm Hg) without medication; minor transient complications were observed in 10 patients. Based on the cumulative survival curve after 48 months, the complete success rate was 32.7% and the qualified success rate, 53.7% (P<.05).
Ex-PRESS R-50 implantation under the conjunctiva was associated with a relatively high number of complications, despite good IOP control in the uncomplicated cases. Refinement in the tube design and implantation technique would increase the success rate.
评估Ex-PRESS R-50植入物(Optonol有限公司)在接受开角型青光眼合并白内障超声乳化手术的眼中的疗效和安全性。
瑞士洛桑大学眼科青光眼科。
2000年11月至2002年6月期间,35例患者的35只眼植入了Ex-PRESS R-50分流器。记录术前以及术后1天、7天、1个月、2个月、3个月、6个月、9个月、12个月、24个月、36个月和48个月时的最佳矫正视力(BCVA)、眼压(IOP)、用药数量和并发症情况。首先进行颞侧透明角膜白内障超声乳化联合人工晶状体植入术。不取出眼科粘弹剂,将Ex-PRESS R-50植入结膜下进入前房。
平均随访时间为36.9个月±18.2(标准差),患者平均年龄为74.6±10.9岁。术前平均眼压为19.3±6.3 mmHg,术后6个月、12个月、24个月、36个月和48个月时分别降至15.3±6.2 mmHg、15.1±4.6 mmHg、13.8±2.8 mmHg、14.6±2.9 mmHg和13.3±2.0 mmHg(P<0.005)。48个月时,平均BCVA为0.74±0.34,用药数量减少了57%(P<0.005)。10例患者取出了微管,10只眼进行了滤泡处理。10例患者(32%)在未用药情况下眼压控制良好(平均13.2±2.2 mmHg);10例患者观察到轻微短暂并发症。根据48个月后的累积生存曲线,完全成功率为32.7%,合格成功率为53.7%(P<0.05)。
尽管在无并发症的病例中眼压控制良好,但结膜下植入Ex-PRESS R-50会出现相对较多的并发症。改进导管设计和植入技术将提高成功率。